


**In the Claims:**

1. (Currently Amended) A compound of formula I



wherein

R<sup>1</sup> is -O-R<sup>4</sup> or -N(R<sup>5</sup>)(R<sup>6</sup>);

R<sup>2</sup> is alkyl or amino;

R<sup>3</sup> is hydrogen, alkyl or halogen;

R<sup>4</sup> is hydrogen, aralkyl, substituted aralkyl, heterocyclalkyl, substituted heterocyclalkyl or cycloalkylalkyl;

R<sup>5</sup> and R<sup>6</sup> are independently selected from hydrogen, alkyl, cycloalkylalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heterocyclyl, substituted heterocyclyl, heterocyclcarbonyl or substituted heterocyclcarbonyl, or

~~R<sup>5</sup> and R<sup>6</sup> together with the N atom to which they are attached form a 5 to 10 membered unsubstituted or substituted heterocyclic ring which optionally comprises a second heteroatom selected from nitrogen or oxygen and, wherein the substituted heterocyclic ring has one or more substituents independently selected from alkyl and alkoxy;~~

A is a 5 to 7-membered saturated unsubstituted or substituted heterocyclic ring comprising the nitrogen atom which is attached to the quinazoline ring and optionally a second heteroatom which is selected from oxygen, sulfur or nitrogen and, wherein the ring A substituted heterocyclic ring has one or more substituents independently selected from halogen, alkyl, alkoxy, haloalkoxy, cycloalkylalkoxy, hydroxy, amino, acetylarnino, cyano, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl and cycloalkylalkoxyalkyl; and pharmaceutically acceptable salts and esters thereof.

2. (Original) The compound according to claim 1, wherein R<sup>2</sup> is alkyl.
3. (Original) The compound according to claim 2, wherein R<sup>2</sup> is methyl.
4. (Original) The compound according to claim 1, wherein R<sup>3</sup> is hydrogen.
5. (Original) The compound according to claim 1, wherein R<sup>1</sup> is -O-R<sup>4</sup>.
6. (Cancelled).
7. (Previously Presented) The compound according to claim 1, wherein R<sup>4</sup> is aralkyl which is benzyl, heterocyclalkyl which is pyridinylmethyl, or aralkyl substituted with cyano, fluoro or chloro; or pyridinylmethyl substituted with cyano, fluoro or chloro.
8. (Original) The compound according to claim 1, wherein R<sup>1</sup> is -N(R<sup>5</sup>)(R<sup>6</sup>).
9. (Cancelled).
10. (Previously Presented) The compound according to claim 1, wherein R<sup>5</sup> or R<sup>6</sup> is hydrogen and the other one is alkyl, pyridinyl, furanylcarbonyl or pyridinyl.
11. (Original) The compound according to claim 1, wherein A is a 5 membered saturated unsubstituted or substituted heterocyclic ring comprising the nitrogen atom which is attached to the quinazoline ring and, wherein the ring A substituted heterocyclic ring has one or more substituents independently selected from alkoxy, hydroxy or hydroxyalkyl.
12. (Original) The compound according to claim 11, wherein A is pyrrolidinyl or pyrrolidinyl substituted with hydroxymethyl, methoxy or ethoxy.

13. (Original) The compound according to claim 1 selected from 4-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yloxymethyl)-benzonitrile; 7-(2-Chloro-pyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-yl-quinazoline; 7-(2-Fluoro-pyridin-3-ylmethoxy)-2-methyl-4-pyrrolidin-1-yl-quinazoline; (S)-{1-[7-(2-Chloro-pyridin-3-ylmethoxy)-2-methyl-quinazolin-4-yl]-pyrrolidin-2-yl}-methanol; (S)-4-[4-(3-Ethoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yloxymethyl]-benzonitrile; Isobutyl-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-amine; (2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-pyridin-3-yl-amine; Furan-2-carboxylic acid (2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-amide; (S)-[4-(3-Ethoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yl]-pyridin-3-yl-amine; and (S)-[4-(3-Methoxy-pyrrolidin-1-yl)-2-methyl-quinazolin-7-yl]-pyridin-3-yl-amine.

14. (Original) A pharmaceutical composition comprising a therapeutically effective amount of a compound in accordance with claim 1 and a pharmaceutically acceptable carrier.

15. (Original) A method of treatment of obesity in a patient in need of such treatment which comprises administering to the patient a therapeutically effective amount of from about 0.1 mg to 20 mg per kg body weight per day of the compound according to claim 1.

16. (Original) A method of treatment of obesity in a patient in need of such treatment which comprises administering to the patient a therapeutically effective amount from about 0.1 mg to 20 mg per kg body weight per day of the compound according to claim 1 and a therapeutically effective amount of from 60 to 720 mg per day of orlistat.

17. (Original) The method according to claim 16 wherein the compound according to claim 1 and the orlistat are administered simultaneously, separately or sequentially.

18. (Original) The pharmaceutical composition of claim 14 further comprising a therapeutically effective amount of orlistat.